Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease

Gastroenterology

Volumn 140, Issue 2, 2011, Pages 425-434.e1

  Tromm, Andreas ^a   Bunganič, Ivan ^b   Tomsová, Eva ^c   Tulassay, Zsolt ^d   Lukáš, Milan ^e   Kykal, Jan ^f   Bátovský, Marian ^g   Fixa, Bohumil ^h   Gabalec, Libor ⁱ   Safadi, Rifaat ^j   Kramm, Heinzjochen ^k   Altorjay, István ^l   Löhr, Hanns ^m   Koutroubakis, Ioannis ⁿ   Barmeir, Simon ^o   Štimac, Davor ^p   Schäffeler, Elke ^a   Glasmacher, Christoph ^q   Dilger, Karin ^r   Mohrbacher, Ralf ^r   Greinwald, Roland ^r   more..

^a Ev Krankenhaus Hattingen GmbH   (Germany)

^b Gastroenterologická Ambulancia GEA S r o   (Slovakia)

^c Regional Hospital Mladá Boleslav   (Czech Republic)

^d Semmelweis Egyetem   (Hungary)

^e CHARLES UNIVERSITY   (Czech Republic)

^f Nemocnice Ricany   (Czech Republic)

^g FNsP Ak Derera   (Slovakia)

^h Hepato Gastroenterologie HK s ro   (Czech Republic)

ⁱ Orlickoustecka Nemocnice A s   (Czech Republic)

^j Israel   (Israel)

^k Akademische Lehrpraxis des Uniklinikums Schleswig Holstein   (Germany)

^l UNIVERSITY OF DEBRECEN   (Hungary)

^m Facharztpraxis   (Germany)

ⁿ UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^o SHEBA MEDICAL CENTER   (Israel)

^p KBC RIJEKA   (Croatia)

^q Medicomp GmbH   (Germany)

^r Dr Falk Pharma GmbH ^*  (Germany)

more..

Author keywords

Mesalamine; Mesalazine; RCT; Remission

Indexed keywords

AZATHIOPRINE; BUDENOFALK; BUDESONIDE; EUDRAGIT; MERCAPTOPURINE; MESALAZINE;

ABDOMINAL PAIN; ACNE; ADULT; AGED; ARTICLE; BACKACHE; CONNECTIVE TISSUE DISEASE; CROHN DISEASE; DISEASE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HEADACHE; HUMAN; HYDROCORTISONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; PANCREATITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS INFECTION; VOMITING;

EID: 79251534064     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2010.11.004     Document Type: Article

References (31)

1. A. Dignass, G. van Assche, and J.O. Lindsay The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management J Crohn Colitis 4 2010 28 62
2. C.H. Seow, E.I. Benchimol, and A.M. Griffiths Budesonide for induction of remission in Crohn's disease Cochrane Database Syst Rev 3 2008 CD000296
3. S. Edsbcker, S. Jonsson, and C. Lindberg Metabolic pathways of the topical glucocorticoid budesonide in man Drug Metab Dispos 11 1983 590 596
4. E.J. Schoon, S. Bollani, and P.R. Mills Matrix Study Group Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease Clin Gastroenterol Hepatol 3 2005 113 121
5. G. Jonsson, A. Astrom, and P. Andersson Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver Drug Metab Dispos 23 1995 137 142
6. K. Dilger, M. Schwab, and M.F. Fromm Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein Inflamm Bowel Dis 10 2004 578 583
7. B.G. Feagan Editorial: 5-ASA therapy for active Crohn's disease: old friends, old data and a new conclusion Clin Gastroenterol Hepatol 2 2004 376 378
8. O.O. Thomsen, A. Cortot, and D. Jewell A comparison of budesonide and mesalamine for active Crohn's disease N Engl J Med 339 1998 370 374
9. B.E. Murphy Some studies of the protein-binding of steroids and their application to the routine micro and ultramicro measurement of various steroids in body fluids by competitive protein-binding radioassay J Clin Endocrinol Metab 27 1967 973 990
10. Y. Meier, C. Pauli-Magnus, and U.M. Zanger Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver Hepatology 44 2006 62 74
11. S. Hoffmeyer, O. Burk, and O. von Richter Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci U S A 97 2000 3473 3478
12. T. Geisler, E. Schaeffeler, and J. Dippon CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation Pharmacogenomics 9 2008 1251 1259
13. ADDPLAN GmbH ADDPLANadaptive designs, plans and analyses Release 2.1 and 4.0. Cologne, Germany 2007
14. W. Lehmacher, and G. Wassmer Adaptive sample size calculations in group sequential trials Biometrics 55 1999 1286 1290
15. C. Jennison, and B.W. Turnbull Group sequential tests and repeated confidence intervals B.K. Ghosh, P.K. Sen, Handbook of sequential analysis 1991 Marcel Dekker New York 283 311
16. EMEA CPMP/EWP/482/99: points to consider on switching between superiority and non-inferiority 2000 EMEA London
17. W.J. Tremaine, S.B. Hanauer, and S. Katz Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States Am J Gastroenterol 97 2002 1748 1754
18. J.W. Singleton, S.B. Hanauer, and G.L. Gitnick Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial Pentasa Crohn's Disease Study Group Gastroenterology 104 1993 1293 1301
19. W.J. Tremaine, K.W. Schroeder, and J.M. Harrison A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis J Clin Gastroenterol 19 1994 278 282
20. C.P. Farrington, and G. Manning Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk Stat Med 9 1990 1447 1454
21. G.R. Greenberg, B.G. Feagan, and F. Martin Oral budesonide for active Crohn's disease Canadian Inflammatory Bowel Disease Study Group N Engl J Med 331 1994 836 841
22. M. Campieri, A. Ferguson, and W. Doe Oral budesonide is as effective as oral prednisolone in active Crohn's disease The Global Budesonide Study Group Gut 41 1997 209 214
23. S.B. Hanauer, and U. Strmberg Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials Clin Gastroenterol Hepatol 2 2004 379 388
24. B. Bokemeyer, A. Katalinic, and T. Klugmann P183predictive factors for a mild course of Crohn's disease J Crohn Colitis 3 2009 S82 S83
25. A. Tromm, T. Griga, and B. May Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties Hepatogastroenterology 46 1999 3124 3135
26. M. Ufer, K. Dilger, and L. Leschhorn Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: a possible role of intestinal CYP3A4 expression Clin Pharmacol Ther 84 2008 43 46
27. C. Marzolini, E. Paus, and T. Buclin Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance Clin Pharmacol Ther 75 2004 13 33
28. R.J. Farrell, A. Murphy, and A. Long High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy Gastroenterology 118 2000 279 288
29. P. Rutgeerts, R. Lofberg, and H. Malchow A comparison of budesonide with prednisolone for active Crohn's disease N Engl J Med 331 1994 842 845
30. V. Gross, T. Andus, and I. Caesar Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease German/Austrian Budesonide Study Group Eur J Gastroenterol Hepatol 8 1996 905 909
31. K.T. Thia, W.J. Sandborn, and J.D. Lewis Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease Am J Gastroenterol 103 2008 3123 3131